Ajanta Pharma Limited announced that its Nomination and Remuneration Committee, in a meeting held on January 30, 2026, approved the vesting of 4,300 cash-settled Stock Appreciation Rights (SARs) on January 31, 2026. These SARs were originally granted on January 30, 2025. The settlement of these vested SARs will be in cash, calculated based on the closing market price of the company's equity shares on the stock exchanges as of February 2, 2026. As these SARs are cash-settled, there will be no issuance of new equity shares and consequently, no dilution to the company's shareholding. Additionally, the committee approved the cancellation of 800 stock options granted under the Share Based Incentive Plan (SBIP). This cancellation is due to the respective grantees ceasing to be employees of the company before the vesting period. The cancelled stock options have been credited back to the ESOP pool.
